Patent US4220657A successfully refreshed from Google Patents.
US4220657A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treatment of human eye disease
Assignee: Individual
•
Filing: 1978-08-11
•
Granted: 1980-09-02
•
Expires: 1998-08-11
Abstract
Abstract Sterile aqueous humor from patients afflicted with the disease endogenous uveitis contains a previously unreported pathogenic microorganism, Micromyces intracellularis, which also has been found in tissue specimens from other diseases. When inoculated into an animal model (e.g., a mouse), the microorganism produces both chronic eye and systemic disease in addition to accelerated mortality and occasional psychotic animal behavior, metabolic disturbances, and neuro-muscular disorders, depending on the mode of inoculation. The animal model therefore provides the basis for a screening process to evaulate chemotherapeutic agents in the treatment of human disease. Using this animal model, a significant decrease in mortality associated with the introduction of Micromyces intracellularis is achieved by the application to the animal model of the chemotherapeutic agents d-2,2'-(ethylenediimino)-di-1-butanol, 4,4'sufonyldianiline, and 3[[(4-methyl-1-piperazinyl)-imino]methyl]-rifamycin SV. These agents are therefore effective in the treatment of diseases having as their etiological agent Micromyces intracellularis, and are particularly useful in the chemotherapy of endogenous uveitis, conjunctivitis and kerato-conjunctivitis.
Inventors
- 👤 Lewis A. Johnson
- 👤 Emil Wirostko
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/859
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
31 words
A method of treating active endogenous uveitis caused by Micromyces intracellularis comprising administering to a patient having endogenous uveitis an effective amount therefor of a therapeutic agent comprising 3 [[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin SV.
Claim 2
Independent Claim
31 words
A method of treating active endogenous uveitis caused by Micromyces intracellularis comprising administering to a patient having endogenous uveitis an effective amount therefor of a therapeutic agent comprising 3 [[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin SV.
Claim 3
Dependent Claim
21 words
A method of treating endogenous uveitis according to claim 1 wherein the therapeutic agent is administered subconjunctivally into the affected eye.
Claim 4
Dependent Claim
24 words
A method of treating endogenous uveitis according to claim 1 wherein the therapeutic agent is administered in the form of an aqueous isotonic solution.
Claim 5
Dependent Claim
17 words
A method of treating endogenous uveitis according to claim 1 wherein the therapeutic agent is administered orally.
Claim 6
Dependent Claim
21 words
A method of treating endogenous uveitis according to claim 1 wherein the therapeutic agent is administered topically to the affected eye.
Claim 7
Independent Claim
29 words
A method of treating chronic conjunctivitis caused by Micromyces intracellularis comprising administering to a patient having chronic conjuntivitis an effective amount therefor of a therapeutic agent comprising 3[[(4-methyl-1piperazinyl)imino]methyl]-rifamycin SV.
Claim 8
Independent Claim
29 words
A method of treating chronic conjunctivitis caused by Micromyces intracellularis comprising administering to a patient having chronic conjuntivitis an effective amount therefor of a therapeutic agent comprising 3[[(4-methyl-1piperazinyl)imino]methyl]-rifamycin SV.
Claim 9
Dependent Claim
21 words
A method of treating chronic conjunctivitis according to claim 6 wherein the therapeutic agent is administered subconjunctivally into the affected eye.
Claim 10
Dependent Claim
24 words
A method of treating chronic conjunctivitis according to claim 6 wherein the therapeutic agent is administered in the form of an aqueous isotonic solution.
Claim 11
Dependent Claim
17 words
A method of treating chronic conjunctivitis according to claim 6 wherein the therapeutic agent is administered orally.
Claim 12
Dependent Claim
21 words
A method of treating chronic conjunctivitis according to claim 6 wherein the therapeutic agent is administered topically to the affected eye.
Claim 13
Independent Claim
27 words
A method of treating kerato-conjunctivitis caused by Micromyces intracellularis comprising administering to a patient having kerato-conjunctivitis an effective amount therefor of a therapeutic agent comprising 3[[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin SV.
Claim 14
Independent Claim
27 words
A method of treating kerato-conjunctivitis caused by Micromyces intracellularis comprising administering to a patient having kerato-conjunctivitis an effective amount therefor of a therapeutic agent comprising 3[[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin SV.
Claim 15
Dependent Claim
20 words
A method of treating kerato-conjunctivitis according to claim 11 wherein the therapeutic agent is administered subconjunctivally into the affected eye.
Claim 16
Dependent Claim
23 words
A method of treating kerato-conjunctivitis according to claim 11 wherein the therapeutic agent is administered in the form of an aqueous isotonic solution.
Claim 17
Dependent Claim
16 words
A method of treating kerato-conjunctivitis according to claim 11 wherein the therapeutic agent is administered orally.
Claim 18
Dependent Claim
20 words
A method of treating kerato-conjunctivitis according to claim 11 wherein the therapeutic agent is administered topically to the affected eye.
Claim 19
Independent Claim
27 words
A method of treating keratitis caused by Micromyces intracellularis comprising administering to a patient having keratitis an effective amount therefor of a therapeutic agent comprising 3[[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin SV.
Claim 20
Independent Claim
27 words
A method of treating keratitis caused by Micromyces intracellularis comprising administering to a patient having keratitis an effective amount therefor of a therapeutic agent comprising 3[[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin SV.
Claim 21
Dependent Claim
20 words
A method of treating keratitis according to claim 16 wherein the therapeutic agent is administered subconjunctivally into the affected eye.
Claim 22
Dependent Claim
23 words
A method of treating keratitis according to claim 16 wherein the therapeutic agent is administered in the form of an aqueous isotonic solution.
Claim 23
Dependent Claim
16 words
A method of treating keratitis according to claim 16 wherein the therapeutic agent is administered orally.
Claim 24
Dependent Claim
20 words
A method of treating keratitis according to claim 16 wherein the therapeutic agent is administered topically to the affected eye.
References Cited (Backward Citations)
US3150046A
Cited
US3342810A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-09-02 | 1984-03-03 | 1984-09-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-09-02 | 1988-03-03 | 1988-09-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-09-02 | 1992-03-03 | 1992-09-02 | $7700.00 | Window Closed / Lapsed |